Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 363

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 363
---
 |   |
| At 31 December 2021                                   |     |       |     |               1,098 |     |              83,434 |   |     |        53,003 |     |     720 |     |                  (127,803 | ) |     |             10,452 |   |

| F-30 |

Notes
forming part of the financial statements

For the years ended 31 December
2023, 2022 and 2021

| 1 | Accounting policies |

General information

Biodexa Pharmaceuticals
PLC (the ‘Company’) is a company registered and domiciled in England and Wales. The Company was incorporated on 12 September
2014.

The Company is a public
limited company, whose ordinary shares were admitted to trading on AIM (‘AIM’), which is a submarket of the London Stock Exchange,
on 8 December 2014 until admission of the Company’s ordinary shares to trading on AIM was cancelled 26 April 2023.

In addition, since 4
December 2015 the Company has American Depository Receipts (‘ADRs’) registered with the US Securities and Exchange Commission
(‘SEC’) and is listed on the NASDAQ Capital Market.

On 27 March 2023 the
company changed its name to Biodexa Pharmaceuticals PLC from Midatech Pharma Plc.

The financial statements
were approved and authorised for issue by the Board of Directors on 18 April 2024.

Basis of preparation

The Group was formed
on 31 October 2014 when the Company entered into an agreement to acquire the entire share capital of Biodexa Limited and its wholly owned
subsidiaries through the issue equivalent of shares in the Company which took place on 13 November 2014.

These financial statements
have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards
Board (IASB).

The principal accounting
policies adopted in the preparation of the financial statements are set out below. The policies have been consistently applied to all
the periods presented.

The consolidated financial
statements have been prepared on a historical cost basis, except for the following item (refer to individual accounting policies for details):

- Certain financial
instruments – fair value through profit or loss.

Adoption of new
and revised standards

New standards, interpretations and amendments effective from 1 January 2023

The Group reviewed the
new standards, interpretations and amendments effective from